PharmiWeb.com - Global Pharma News & Resources

Pharmaco - Press Releases

Date Title Company
22-Mar-2023 PolyPeptide publishes invitation to the annual General Meeting 2023 PolyPeptide Group
22-Mar-2023 Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023 Relief Therapeutics Holding SA
21-Mar-2023 Vaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical Lesions Vaccitech
21-Mar-2023 AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline AC Immune
21-Mar-2023 Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia Karuna Therapeutics
21-Mar-2023 LYNPARZA (OLAPARIB) APPROVED IN THE UK AS COMBINATION THERAPY FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHEN CHEMOTHERAPY IS NOT CLINICALLY INDICATED AstraZeneca
21-Mar-2023 2023 PM Society Awards – Winners Announced PM Society
21-Mar-2023 LYNPARZA (OLAPARIB) APPROVED IN THE UK AS COMBINATION THERAPY FOR TREATMENT OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHEN CHEMOTHERAPY IS NOT CLINICALLY INDICATED AstraZeneca and MSD
21-Mar-2023 Evotec SE to announce preliminary financial results for fiscal year 2022 on 28 March 2023 Evotec SE
21-Mar-2023 aap receives US-American clearance (FDA) for polyaxial LOQTEQ® VA Elbow system; launch planned for Q4 2023 aap Implantate AG
21-Mar-2023 Mainz Biomed to Present at Sidoti Virtual Investor Conference March 22-23 Mainz BioMed N.V.
20-Mar-2023 New clinical study demonstrates Medacta’s MySpine accuracy in screw replacement during spine revision surgery Medacta Group SA
20-Mar-2023 AEVIS VICTORIA SA – Consolidated EBITDA 2022 up by more than 60% to between CHF 125 and 130 million (2021: CHF 78.4m); net profit 2022 will exceed CHF 60 million (2021: CHF 4.6m) AEVIS VICTORIA SA
20-Mar-2023 Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia Newron Pharmaceuticals S.p.A.
17-Mar-2023 Relief Therapeutics to Present Pre-Clinical Evidence for Improved Amino Acid Utilization with PKU GOLIKE at the Society for Inherited Metabolic Disorders 44th Annual Meeting Relief Therapeutics Holding SA
17-Mar-2023 Tiziana Life Sciences Highlighted in Forbes Article Tiziana Life Sciences
17-Mar-2023 PHARMANOVIA ENTERS INTO AN EXCLUSIVE LICENSING AGREEMENT WITH AETERNA ZENTARIS FOR THE FIRST AND ONLY ORALLY ADMINISTERED APPROVED MEDICINE FOR THE DIAGNOSIS OF GROWTH HORMONE DEFICIENCY IN ADULTS Pharmanovia
17-Mar-2023 Aitia and UCB Announce Strategic Drug Discovery Collaboration in Huntington's Disease UCB
17-Mar-2023 CPHI Pharma Awards open to global innovators, scientists, entrepreneurs and social leaders CPHI Pharma Awards
17-Mar-2023 Enzo Biochem Agrees to Sell Clinical Laboratory to Labcorp Enzo Biochem